logo
Mounjaro: Everything You Need To Know About This Medication

Mounjaro: Everything You Need To Know About This Medication

NDTV2 days ago

Mounjaro is the brand name for tirzepatide, a prescription medication developed by Eli Lilly that is primarily used to treat type 2 diabetes in adults. It is a once-weekly injectable drug that helps manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Mounjaro is unique because it's the first medication approved that targets both these hormones, offering better blood sugar control and weight loss compared to existing GLP-1 receptor agonists. Recently, it has also gained attention for its significant weight-loss effects, even in people who are overweight or obese but do not have diabetes, though this use may vary by country and approval status. Keep reading as we discuss everything you need to know about this medication.
Everything you need to know about mounjaro
How it works
Mounjaro helps lower blood glucose by stimulating insulin release when blood sugar is high and reducing the amount of sugar produced by the liver. It also slows down digestion, which reduces the speed at which sugar enters the bloodstream after eating. The GIP component may enhance how the body responds to insulin and help reduce appetite, leading to gradual, sustained weight loss in many users.
Benefits
Apart from effective blood sugar control, Mounjaro has shown significant benefits in weight management, with some clinical trials showing up to 20% body weight loss in participants. This makes it a promising option for people with type 2 diabetes and those struggling with obesity-related health issues. It may also lower the risk of cardiovascular events and improve cholesterol levels, though long-term studies are still underway.
Possible side effects
Like many medications, Mounjaro can come with side effects. Common ones include nausea, vomiting, diarrhoea, constipation, and loss of appetite, especially when starting the drug or increasing the dose. These symptoms often subside as the body adjusts. More serious but rare side effects include pancreatitis, gallbladder issues, kidney problems due to dehydration, and severe gastrointestinal issues. There is also a black box warning due to the risk of thyroid C-cell tumours, including medullary thyroid carcinoma, observed in animal studies so it's not recommended for people with a personal or family history of such conditions.
Who should avoid it
Mounjaro is not approved for use in people with type 1 diabetes, and those with a history of pancreatitis, gallbladder disease, or medullary thyroid carcinoma should avoid it. It's also not typically recommended during pregnancy or breastfeeding unless deemed absolutely necessary by a healthcare provider. Always consult a doctor to evaluate if it's the right fit.
Administration and monitoring
Mounjaro is injected subcutaneously (under the skin) once a week, usually in the thigh, stomach, or upper arm. It's important to monitor blood sugar levels, weight, and digestive symptoms during the course of treatment. Regular kidney function tests, liver function panels, and monitoring for any abdominal symptoms are advisable while on this medication.
Mounjaro represents a breakthrough in diabetes and weight management due to its dual-hormone approach. However, it is not a quick fix. It works best when combined with lifestyle changes such as a balanced diet, regular physical activity, and close medical supervision. While its effects are promising, it's crucial to use it responsibly and only under medical guidance.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?
NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?

Business Standard

time9 hours ago

  • Business Standard

NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?

Just when many believed Covid-19 was in the rear-view mirror, a new variant has quietly gained ground. NB.1.8.1, first detected in China in January 2025, now accounts for one in ten Covid-19 cases globally—up from just one in forty a month ago. It has spread across twenty-two countries so far. What is NB.1.8.1 variant? According to the World Health Organization, NB.1.8.1 is among several fast-evolving Omicron-lineage variants. From January to May 2025, global dominance shifted from XEC to LP.8.1, with NB.1.8.1 now surging rapidly. The WHO has classified NB.1.8.1 as a Variant Under Monitoring due to its rise in prevalence and potential public health implications. Officials stress that while vigilance is crucial, there is no cause for alarm. Vaccination remains the best protection against severe illness and death. How NB.1.8.1 behaves and how severe it really is NB.1.8.1 is a sublineage of the Omicron JN.1 family. It carries similar characteristics—high transmissibility, but mostly mild to moderate illness. It also includes new mutations on the spike protein, which may enhance its ability to spread and evade immunity. So far, there is no evidence to suggest NB.1.8.1 causes more severe disease, hospitalisations or death compared to previous variants. NB.1.8.1 symptoms: What to watch for Common symptoms include: Dry, persistent cough Runny or blocked nose Fatigue and general body aches Sore throat Fever or chills Headache or hoarseness in some cases Many report being able to go about daily activities but feel unusually tired and sluggish. Are vaccines still effective against NB.1.8.1? Updated vaccines, including the latest Omicron-targeted boosters, are designed to protect against the JN.1 family. While they may not prevent all infections, they continue to reduce the risk of hospitalisation and severe outcomes. Expert guidance includes: If you are over sixty, have chronic health conditions or are immunocompromised, get a booster if it has been more than six months since your last dose If you are healthy and under sixty, no new dose is required at present Use masks in public transport and crowded indoor spaces How to manage NB.1.8.1 symptoms at home In most cases, NB.1.8.1 does not require hospitalisation. Here is what helps: Rest and stay well hydrated Use paracetamol or other over-the-counter medications for fever or aches Recovery generally takes five to seven days If you are elderly or immunocompromised, speak to your doctor early. Antiviral medication is most effective within five days of the onset of symptoms. Warning signs: When to seek emergency help Seek urgent medical care if you experience any of the following: Difficulty breathing Chest pain or tightness Confusion or trouble staying awake Severe dizziness or fainting Do not panic, but stay informed Experts believe NB.1.8.1 will follow a familiar seasonal pattern seen with earlier variants—periodic surges during winter and summer months. Most infections remain mild. Vaccines continue to work. Keep an eye on symptoms, isolate if unwell, and consult your doctor when in doubt.

Covid infections growing milder, occasional surges expected but don't worry: experts
Covid infections growing milder, occasional surges expected but don't worry: experts

New Indian Express

time11 hours ago

  • New Indian Express

Covid infections growing milder, occasional surges expected but don't worry: experts

The death toll is 55 in the current surge which started January this year, primarily among individuals with pre-existing illnesses, according to the Union Health ministry. "People with pre-existing illnesses and those older than 65 should follow standard precautions, as they would against any other respiratory infection -- not just for COVID-19," explained Lahariya, a consultant physician and former staff member of WHO. Kerala is the most affected with over 1,600 cases, followed by Gujarat, West Bengal, Delhi and Maharashtra, ministry data shows. The case surge in India is part of a wider wave impacting parts of Southeast Asia, including Singapore, Malaysia, Thailand and Hong Kong, which have been seeing a rise in infections over the past months. Wastewater surveillance by the Council of Scientific and Industrial Research-National Chemical Laboratory (NCL) has detected presence of SARS-CoV-2 -- which causes COVID-19 -- in samples from 10 sewage treatment plants in Pune, the Times of India reported. Patterns are similar to those seen in the weeks preceding earlier surges, NCL scientists were quoted as saying. Genome sequencing of samples from India's west and south have shown links to the subvariants of Omicron -- LF.7, XFG, JN.1 and NB.1.8.1. The cases are not severe and there is no need to worry, Director General of Indian Council of Medical Research (ICMR) Rajiv Behl said earlier this week. LF.7 and been classified as 'variants under monitoring' (VUM) by the WHO to alert public health authorities that a variant of SARS-CoV-2 requires prioritised attention and monitoring. JN.1 has been circulating in India since November 2023. The current situation, Behl stressed, is being monitored. Immunologist Satyajit Rath explained that the subvariants driving up case numbers indicate that they are probably better at binding themselves to human cells, despite pre-existing antibodies created in response to a prior infection or vaccination -- or 'infectivity'. "However, the important issue here is not their infectivity, but their tendency to cause severe disease, or 'virulence'," Rath, former scientist at New Delhi's National Institute of Immunology, told PTI. "Since selection pressure among the virus strains depends on infectivity and transmissibility -- and not on virulence -- there is no reason to expect a steady increase in the virulence of the emerging virus strains, which, in fact, has not at all been seen either," he added. Moreover, given that the COVID-19-causing virus is now endemic and constantly 'mutating' or evolving, ups and downs in infections in the population are expected, the health experts said. "People need not worry themselves until they are informed of a new 'variant of concern'. VUM is not relevant to the public, but only to public health authorities," Agarwal said. Lahariya advised the public to gather information from reliable sources and not to forward unverified messages, while Rath suggested that citizens keep a watch for the virulence of newly emerging strains. The experts also stressed on the role of authorities. "National and state governments in India should keep a watch on cases, monitor the trends in new cases and share data widely. The linkage between infections and clinical outcomes should be explored to understand the clinical features of the variants in circulation," Lahariya said. Rath drew attention to systemic issues that remain regarding preparedness of public health systems and availability of healthcare facilities across sections of the society should a virulent variant emerge. "The catch is, how efficiently, systematically and rigorously are our public health systems tracking virus strains, their infectivity and their virulence, not only for SARS-CoV-2 but for any other infection?" he asked. "Are we making next generation Covid vaccines at all? Are we making them available widely and affordably? Are we even carefully tracking evidence to see how well or poorly the current vaccine-induced immunity functions against emerging strains?" he added. The poor and vulnerable would need special protection "but are masks being made widely and freely available? “And if not, we are throwing poor communities onto their own resources even for taking such simple precautions, and that is a systemic problem," Rath said.

Covid in India latest update: Active cases rise to 5364, Delhi reports 562 cases, Maharashtra at..., Kerala leads with...,
Covid in India latest update: Active cases rise to 5364, Delhi reports 562 cases, Maharashtra at..., Kerala leads with...,

India.com

time14 hours ago

  • India.com

Covid in India latest update: Active cases rise to 5364, Delhi reports 562 cases, Maharashtra at..., Kerala leads with...,

Covid in India latest update: Active cases rise to 5364, Delhi reports 562 cases, Maharashtra at..., Kerala leads with..., India is once again witnessing a big rise in COVID-19 cases across the country. As of now, the number of active COVID-19 cases in the country stands at 5,364. At the same time, 4,724 people have recovered and been discharged from hospitals and home isolation across different states. Kerala leads the chart with 1,679 cases, followed by Gujrat (615), West Bengak (596) and Delhi (562). Here's a quick look at active cases in some major states: Delhi – 562 cases Gujarat – 615 cases Karnataka – 451 cases Kerala – 1,679 cases Maharashtra – 548 cases Rajasthan – 107 cases Tamil Nadu – 221 cases Uttar Pradesh – 205 cases West Bengal – 596 cases Unfortunately, four COVID-related deaths have also been reported. Karnataka: 1 Death A 65-year-old man passed away. He was also suffering from high blood pressure and uncontrolled diabetes. His COVID-19 infection was found incidentally while treating other conditions. Kerala: 2 Deaths A 74-year-old woman, who had multiple health problems including severe heart valve disease, COPD, high blood pressure, and diabetes, died after testing positive for COVID-19. A 79-year-old man, also from Kerala, passed away. He had high blood pressure, a history of stroke, liver disease, and a urinary tract infection caused by bacteria. Punjab: 1 Death A 69-year-old woman lost her life. She had pulmonary thromboembolism (a serious lung condition), along with morbid obesity. Health officials continue to keep a close watch on the situation. People, especially those with other health issues, are advised to take precautions and avoid crowded places if feeling unwell. PTI INFOGRAPHICS on covid cases across India Covid Variants As of May 2025, the World Health Organization (WHO) has identified LF.7 and NB.1.8.1 as Variants Under Monitoring. This means these new subvariants of the COVID-19 virus are being closely watched but are not yet classified as Variants of Concern (VOC) or Variants of Interest (VOI). However, health experts believe that these strains may be playing a role in the recent spike in infections, not only in India, but also in China and other parts of Asia. While more research is still underway, authorities are urging the public to remain cautious, especially those with underlying health conditions or weakened immunity. Even though new COVID-19 subvariants are being detected, JN.1 is still the most common strain in India. It makes up a massive 53% of all positive cases across the country right now. According to the latest report from the Indian SARS-CoV-2 Genomics Consortium (INSACOG): One case of the subvariant NB.1.8.1 was found in Tamil Nadu in April. Four cases of LF.7 were identified in Gujarat earlier in June. Health experts say that while these newer strains are being closely monitored, JN.1 remains the main cause behind the current wave of infections. People are being urged to stay cautious, especially those with health risks or low immunity.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store